{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:58:03Z","timestamp":1787313483739,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T00:00:00Z","timestamp":1610841600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T00:00:00Z","timestamp":1610841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s11060-021-03695-w","type":"journal-article","created":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T06:02:10Z","timestamp":1610863330000},"page":"265-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Neurotoxicities associated with immune checkpoint inhibitor therapy"],"prefix":"10.1007","volume":"152","author":[{"given":"Sophie L.","family":"Duong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Barbiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7755-6793","authenticated-orcid":false,"given":"Joachim M.","family":"Baehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,17]]},"reference":[{"issue":"1","key":"3695_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"issue":"19","key":"3695_CR2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O\u2019Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016) Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N Engl J Med 375(19):1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"issue":"19","key":"3695_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu L-A, Waxman IM, Sharma P (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"issue":"12","key":"3695_CR4","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/nrd.2018.210","volume":"17","author":"J Tang","year":"2018","unstructured":"Tang J, Yu JX, Hubbard-Lucey VM, Neftelinov ST, Hodge JP, Lin Y (2018) Trial watch: The clinical trial landscape for PD1\/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov 17(12):854\u2013855. https:\/\/doi.org\/10.1038\/nrd.2018.210","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"3695_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252\u2013264. https:\/\/doi.org\/10.1038\/nrc3239","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"3695_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"3695_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R, Carpentier AF (2017) Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer 73:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"3695_CR8","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","volume":"82","author":"D Makarious","year":"2017","unstructured":"Makarious D, Horwood K, Coward JIG (2017) Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer 82:128\u2013136. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.041","journal-title":"Eur J Cancer"},{"issue":"6","key":"3695_CR9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/wco.0000000000000503","volume":"30","author":"M Touat","year":"2017","unstructured":"Touat M, Talmasov D, Ricard D, Psimaras D (2017) Neurological toxicities associated with immune-checkpoint inhibitors. Curr Opin Neurol 30(6):659\u2013668. https:\/\/doi.org\/10.1097\/wco.0000000000000503","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"3695_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","volume":"4","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM (2018) Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 4(2):173\u2013182. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"issue":"8","key":"3695_CR11","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","volume":"73","author":"TJ Williams","year":"2016","unstructured":"Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Avila AL, Le DT, Lipson EJ, Probasco JC, Mowry EM (2016) Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73(8):928\u2013933. https:\/\/doi.org\/10.1001\/jamaneurol.2016.1399","journal-title":"JAMA Neurol"},{"issue":"3","key":"3695_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","volume":"137","author":"A Fellner","year":"2018","unstructured":"Fellner A, Makranz C, Lotem M, Bokstein F, Taliansky A, Rosenberg S, Blumenthal DT, Mandel J, Fichman S, Kogan E, Steiner I, Siegal T, Lossos A, Yust-Katz S (2018) Neurologic complications of immune checkpoint inhibitors. J Neuro-Oncol 137(3):601\u2013609. https:\/\/doi.org\/10.1007\/s11060-018-2752-5","journal-title":"J Neuro-Oncol"},{"issue":"2","key":"3695_CR13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/annonc\/mdw558","volume":"28","author":"L Spain","year":"2017","unstructured":"Spain L, Walls G, Julve M, O\u2019Meara K, Schmid T, Kalaitzaki E, Turajlic S, Gore M, Rees J, Larkin J (2017) Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol 28(2):377\u2013385. https:\/\/doi.org\/10.1093\/annonc\/mdw558","journal-title":"Ann Oncol"},{"issue":"10","key":"3695_CR14","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","volume":"74","author":"JC Kao","year":"2017","unstructured":"Kao JC, Liao B, Markovic SN, Klein CJ, Naddaf E, Staff NP, Liewluck T, Hammack JE, Sandroni P, Finnes H, Mauermann ML (2017) Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74(10):1216\u20131222. https:\/\/doi.org\/10.1001\/jamaneurol.2017.1912","journal-title":"JAMA Neurol"},{"key":"3695_CR15","unstructured":"National Cancer Institute (2017) CTCAE v5.0 Quick Reference 8.5x11. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed 20 Mar 2019"},{"key":"3695_CR16","volume-title":"IBM SPSS statistics for Macintosh, Version 25.0","author":"IBM Corp","year":"2017","unstructured":"IBM Corp (2017) IBM SPSS statistics for Macintosh, Version 25.0. IBM Corp., Armonk, NY"},{"issue":"16","key":"3695_CR17","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/wnl.0000000000002594","volume":"86","author":"Y Cao","year":"2016","unstructured":"Cao Y, Nylander A, Ramanan S, Goods BA, Ponath G, Zabad R, Chiang VL, Vortmeyer AO, Hafler DA, Pitt D (2016) CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology 86(16):1553\u20131556. https:\/\/doi.org\/10.1212\/wnl.0000000000002594","journal-title":"Neurology"},{"issue":"6382","key":"3695_CR18","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"issue":"14","key":"3695_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbe C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345\u20131356. https:\/\/doi.org\/10.1056\/NEJMoa1709684","journal-title":"N Engl J Med"},{"issue":"4","key":"3695_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob J-J, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16(4):375\u2013384. https:\/\/doi.org\/10.1016\/S1470-2045(15)70076-8","journal-title":"Lancet Oncol"},{"issue":"6","key":"3695_CR21","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/wco.0000000000000391","volume":"29","author":"AF Hottinger","year":"2016","unstructured":"Hottinger AF (2016) Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29(6):806\u2013812. https:\/\/doi.org\/10.1097\/wco.0000000000000391","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"3695_CR22","doi-asserted-by":"publisher","first-page":"e1093","DOI":"10.1212\/wnl.0000000000008091","volume":"93","author":"D Dubey","year":"2019","unstructured":"Dubey D, David WS, Amato AA, Reynolds KL, Clement NF, Chute DF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC (2019) Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology 93(11):e1093\u2013e1103. https:\/\/doi.org\/10.1212\/wnl.0000000000008091","journal-title":"Neurology"},{"issue":"4","key":"3695_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.29245\/2572.942X\/2016\/4.1040","volume":"1","author":"JT Blackmon","year":"2016","unstructured":"Blackmon JT, Viator TM, Conry RM (2016) Central nervous system toxicities of anti-cancer immune checkpoint blockade. J Neurol Neuromed 1(4):39\u201345","journal-title":"J Neurol Neuromed"},{"key":"3695_CR24","doi-asserted-by":"publisher","unstructured":"Maurice C, Schneider R, Kiehl T-R, Bavi P, Roehrl MHA, Mason WP, Hogg D (2015) Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res. https:\/\/doi.org\/10.1158\/2326-6066.Cir-15-0141","DOI":"10.1158\/2326-6066.Cir-15-0141"},{"issue":"6","key":"3695_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","volume":"22","author":"J Larkin","year":"2017","unstructured":"Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, Suijkerbuijk KPM, Azevedo S, Li H, Reshef D, Avila A, Reardon DA (2017) Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist 22(6):709\u2013718. https:\/\/doi.org\/10.1634\/theoncologist.2016-0487","journal-title":"Oncologist"},{"issue":"1","key":"3695_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40425-018-0393-z","volume":"6","author":"CA Garcia","year":"2018","unstructured":"Garcia CA, El-Ali A, Rath TJ, Contis LC, Gorantla V, Drappatz J, Davar D (2018) Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. J Immunother Cancer 6(1):83. https:\/\/doi.org\/10.1186\/s40425-018-0393-z","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3695_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11060-014-1359-8","volume":"117","author":"A Alomari","year":"2014","unstructured":"Alomari A, Rauch PJ, Orsaria M, Minja FJ, Chiang VL, Vortmeyer AO (2014) Radiologic and histologic consequences of radiosurgery for brain tumors. J Neuro-Oncol 117(1):33\u201342. https:\/\/doi.org\/10.1007\/s11060-014-1359-8","journal-title":"J Neuro-Oncol"},{"issue":"8","key":"3695_CR28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41571-018-0046-7","volume":"15","author":"WL Hwang","year":"2018","unstructured":"Hwang WL, Pike LRG, Royce TJ, Mahal BA, Loeffler JS (2018) Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol 15(8):477\u2013494. https:\/\/doi.org\/10.1038\/s41571-018-0046-7","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"3695_CR29","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.3390\/ijms19103054","volume":"19","author":"EJ Lehrer","year":"2018","unstructured":"Lehrer EJ, McGee HM, Peterson JL, Vallow L, Ruiz-Garcia H, Zaorsky NG, Sharma S, Trifiletti DM (2018) Stereotactic radiosurgery and immune checkpoint inhibitors in the management of brain metastases. Int J Mol Sci 19(10):3054. https:\/\/doi.org\/10.3390\/ijms19103054","journal-title":"Int J Mol Sci"},{"issue":"16","key":"3695_CR30","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMra023009","volume":"349","author":"RB Darnell","year":"2003","unstructured":"Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349(16):1543\u20131554. https:\/\/doi.org\/10.1056\/NEJMra023009","journal-title":"N Engl J Med"},{"issue":"11","key":"3695_CR31","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/wnl.0000000000004359","volume":"89","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K, Uhara H, Hasegawa Y, Inomata S, Otani Y, Yokota K, Hirose T, Tanaka R, Suzuki N, Matsui M (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127\u20131134. https:\/\/doi.org\/10.1212\/wnl.0000000000004359","journal-title":"Neurology"},{"key":"3695_CR32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, G\u00f6ppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210\u2013225. https:\/\/doi.org\/10.1016\/j.ejca.2016.02.024","journal-title":"Eur J Cancer"},{"key":"3695_CR33","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jocn.2017.07.014","volume":"45","author":"Y Gu","year":"2017","unstructured":"Gu Y, Menzies AM, Long GV, Fernando SL, Herkes G (2017) Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci 45:14\u201317. https:\/\/doi.org\/10.1016\/j.jocn.2017.07.014","journal-title":"J Clin Neurosci"},{"issue":"17","key":"3695_CR34","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/jco.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Chakrabarty JH, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA, Network icwtNCC (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/jco.2017.77.6385","journal-title":"J Clin Oncol"},{"issue":"28","key":"3695_CR35","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/jco.2015.60.8448","volume":"33","author":"TZ Horvat","year":"2015","unstructured":"Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D\u2019Angelo SP, Woo KM, Panageas KS, Wolchok JD, Chapman PB (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33(28):3193\u20133198. https:\/\/doi.org\/10.1200\/jco.2015.60.8448","journal-title":"J Clin Oncol"},{"issue":"1","key":"3695_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/jipo.Jipo_12_18","volume":"1","author":"H Abu-Sbeih","year":"2018","unstructured":"Abu-Sbeih H, Tang T, Ali F, Johnson D, Qiao W, Diab A, Wang Y (2018) The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients\u2019 outcomes. J Immunother Precis Oncol 1(1):7\u201318. https:\/\/doi.org\/10.4103\/jipo.Jipo_12_18","journal-title":"J Immunother Precis Oncol"},{"issue":"Suppl 4","key":"3695_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2019-000540","volume":"4","author":"L Spain","year":"2019","unstructured":"Spain L, Tippu Z, Larkin JM, Carr A, Turajlic S (2019) How we treat neurological toxicity from immune checkpoint inhibitors. ESMO Open 4(Suppl 4):e000540. https:\/\/doi.org\/10.1136\/esmoopen-2019-000540","journal-title":"ESMO Open"},{"issue":"8","key":"3695_CR38","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O\u2019Day SJ, Ascierto PA, Salama AKS, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908\u2013918. https:\/\/doi.org\/10.1016\/S1470-2045(15)00083-2","journal-title":"Lancet Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03695-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-021-03695-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-021-03695-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T10:34:31Z","timestamp":1616754871000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-021-03695-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,17]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["3695"],"URL":"https:\/\/doi.org\/10.1007\/s11060-021-03695-w","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,17]]},"assertion":[{"value":"15 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Study design and methods were approved by the institutional review board of Yale School of Medicine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}